Search

This paper outlines our practice to enhance the findability and searchability of research data through metadata conversion from the Space Physics Archive Search and Extract (SPASE) schema to a more generic schema, the Japan Consortium for Open Access Repository (JPCOAR) schema, and its registration in institutional repositories. Traditionally, earth and space science research data have been organized using the SPASE schema. Although the SPASE schema is comprehensive, its usage has been restricted to highly professional databases, limiting broader accessibility and impeding cross-disciplinary research. We discuss a case study at Nagoya University where 284 metadata records were converted from SPASE to JPCOAR, and illustrate the process and benefits of this conversion. This approach significantly improved the visibility and usability of metadata across various platforms like the Institutional Repositories DataBase (IRDB), the Data Catalog Cross-Search System, and Google Dataset Search, extending access to a wider range of users beyond the highly professional scientific community. This approach also aligns with national policies in Japan on research data management and simplifies metadata handling for researchers. Future direction includes expanding this conversion and registration model to other universities and institutions by leveraging the ubiquity of the SPASE schema in the earth and space science fields. Our practice may be useful in other research fields. This initiative aims to improve the overall findability of research data, to foster cross-disciplinary collaboration, and to enhance the value of research data itself and of creators and managers of the data.

Background and Objectives: In this study, our objective was to assess and compare the changes in visual and structural outcomes among patients with neovascular age-related macular degeneration (nAMD) who were switched from intravitreal aflibercept (IVA) to either intravitreal brolucizumab (IVBr) or intravitreal faricimab (IVF) injections in a clinical setting. Materials and Methods: This observational clinical study included 20 eyes of 20 patients switched to brolucizumab and 15 eyes of 14 patients switched to faricimab from aflibercept in eyes with nAMD. We measured the structural outcome (central macular thickness (CMT)) and the visual outcome (best-corrected visual acuity (BCVA); logMAR) as follows: just before the most recent IVA injection (B0), one month after the most recent IVA injection (B1), just before the first IVBr or IVF injection (A0), one month after (A1) and three months after (A3) the first IVBr or IVF injection. Results: BCVA showed significant improvement at A1 (0.25 ± 0.34) and at A3 (0.19 ± 0.24) compared to A0 (0.38 ± 0.35) in the IVBr group (p = 0.0156, p = 0.0166, respectively). CMT (μm) was significantly thinner at A1 (IVBr: 240.55 ± 51.82, IVF: 234.91 ± 47.29) and at A3 (IVBr: 243.21 ± 76.15, IVF: 250.50 ± 72.61) compared to at A0 (IVBr: 303.55 ± 79.18, IVF: 270.33 ± 77.62) in the IVBr group (A1: p = 0.0093, A3: p = 0.0026) and in the IVF group (A1: p = 0.0161, A3: p = 0.0093). There was no significant difference in BCVA and CMT improvement observed between two groups at any time point (p > 0.05 for all). Conclusions: Switching from aflibercept to either brolucizumab or faricimab has a significant anatomical effect in eyes with nAMD and both treatments appear to be effective short-term treatment options. There is a trend towards greater visual improvements and reductions in CMT with brolucizumab.

Spectropolarimetric observation of a quiescent prominence was performed in He i 1083 nm. With the slit of the spectrograph fixed on the prominence, we obtained a time series of Stokes profiles for a duration of 108 minutes with a cadence of 8 s. Also using imaging spectroscopic data in H α and extreme-ultraviolet images at 193 Å, we obtained the following results: (1) The prominence harbors persistent waves propagating across its body. (2) The waves are conspicuous in the line-of-sight (LOS) velocity with an amplitude of about 2 km s ^−1 but not detectable in the intensity of emission lines or magnetic field. (3) Noticeable periods are about 4 minutes (220 and 260 s) and 15 minutes (910 s), and they propagate with phase speeds of 140 ∼ 200 and ∼24 km s ^−1 preferentially in horizontal and vertical directions, respectively. (4) Magnetic field strength was estimated to be about 2.5 G with its LOS component of 0 ± 1 G on average. We interpret the 4 minute oscillation as Alfvénic waves propagating in the corona containing the prominence threads, and it is not a resonant wave trapped in the prominence body but excited by an external source. On the other hand, a 15 minute oscillation is interpreted as Alfvénic waves propagating upward in the prominence body. The prominence was evolving in its height during our observation, and there is a hint that the 15 minute period gradually gets longer during the observation. These waves are thought to be taking place in layers with different field directions and strength superposed in the LOS.